Search

Displaying results 3651 - 3660 of 5897 in total
  1. Drug

    CZEN 002

    go.drugbank.com/drugs/DB05479
    Experimental

    (6-9) that is important for binding to the known melanocortin receptors. … It appears that CZEN-002 works on a receptor in yeast that has yet to be identified.

  2. Drug

    MDX-214

    go.drugbank.com/drugs/DB06110
    Experimental

    MDX-214 consists of recombinant human epidermal growth factor (EGF) genetically linked to a fully human antibody fragment that is designed to activate cytotoxic killing of cancer cells by immune effector

  3. Drug

    CR002

    go.drugbank.com/drugs/DB05139
    Investigational

    This is a novel therapeutic approach to treat kidney inflammation. … CR002 is a novel investigational fully human monoclonal antibody that blocks the activity of excess platelet-derived growth factor-D (PDGF-D), a target shown to play a role in kidney inflammation.

  4. Drug

    Otelixizumab

    go.drugbank.com/drugs/DB05496
    Investigational

    Otelixizumab is a monoclonal antibody that binds to a receptor found on all T cells called CD3, which is involved in normal T cell signaling. … Tolerx is developing otelixizumab to treat patients with type 1 diabetes, psoriasis and other autoimmune diseases such as rheumatoid arthritis.

  5. Drug

    RGX-121

    go.drugbank.com/drugs/DB17681
    Investigational

    RGX-121 is designed to use the NAV AAV9 vector to deliver the human iduronate-2-sulfatase gene to the central nervous system.

  6. Drug

    Phenserine

    go.drugbank.com/drugs/DB04892
    Investigational

    Axonyx announced on 20 September 2005 that phenserine was ineffective in two curtailed phase 3 trials. … If this is substantiated in an ongoing clinical trial then phenserine may open the door to an entirely new type of treatment for AD.

  7. Drug

    Anumigilimab

    go.drugbank.com/drugs/DB16359
    Investigational

    CSL324 is a fully human anti-G-CSFR antibody shown to have the ability to control G-CSF-mediated neutrophilia in cynomolgus macaques.

  8. Drug

    Cetilistat

    go.drugbank.com/drugs/DB06586
    Investigational

    Cetilistat is a novel inhibitor of pancreatic lipase being developed by Alizyme for the treatment of obesity and associated co-morbidities, including type 2 diabetes.

  9. Drug

    Arbaclofen Placarbil

    go.drugbank.com/drugs/DB08892
    Investigational

    Arbaclofen Placerbil was believed to have therapeutic potential in treating gastroesophogeal reflux disease (GERD) and plasticity; however due to discouraging clinical trial results, the drug was abandoned … On May 20th, 2013, XenoPort announced plans to terminate the development of Arbaclofen Placerbil for the treatment of multiple sclerosis.

  10. Drug

    Anacaulase

    go.drugbank.com/drugs/DB17449
    ApprovedInvestigational

    It is mostly composed (80-95% w/w) of proteins such as stem bromelain, ananain, jacalin-like lectin, bromelain inhibitors, and phytocystatin inhibitor, as well as saccharides, as both free monosaccharides … Therefore, enzymatic alternatives such as anacaulase can lead to better clinical outcomes.